| 1 | Childhood, adolescent, and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers | 4.6 | 6 | Citations (PDF) |
| 2 | Using polygenic risk modification to improve breast cancer prevention: study protocol for the PRiMo multicentre randomised controlled trial | 1.9 | 9 | Citations (PDF) |
| 3 | Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatment | 8.6 | 14 | Citations (PDF) |
| 4 | Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores | 4.6 | 41 | Citations (PDF) |
| 5 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants | 4.2 | 29 | Citations (PDF) |
| 6 | Rare germline copy number variants (CNVs) and breast cancer risk | 4.4 | 14 | Citations (PDF) |
| 7 | Polygenic risk modeling for prediction of epithelial ovarian cancer risk | 3.0 | 61 | Citations (PDF) |
| 8 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes | 4.7 | 28 | Citations (PDF) |
| 9 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes | 14.3 | 121 | Citations (PDF) |
| 10 | Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer | 6.4 | 16 | Citations (PDF) |
| 11 | Breast cancer risks associated with missense variants in breast cancer susceptibility genes | 9.6 | 53 | Citations (PDF) |
| 12 | Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci | 4.6 | 13 | Citations (PDF) |
| 13 | Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk | 4.6 | 56 | Citations (PDF) |
| 14 | Population-based targeted sequencing of 54 candidate genes identifies
PALB2
as a susceptibility gene for high-grade serous ovarian cancer | 3.8 | 48 | Citations (PDF) |
| 15 | Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population‐based cohort studies and two‐sample Mendelian randomization analyses | 4.3 | 18 | Citations (PDF) |
| 16 | CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers | 5.5 | 8 | Citations (PDF) |
| 17 | A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers | 13.7 | 39 | Citations (PDF) |
| 18 | RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors | 10.6 | 70 | Citations (PDF) |
| 19 | Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women | 34.5 | 1,036 | Citations (PDF) |
| 20 | Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer | 1.6 | 10 | Citations (PDF) |
| 21 | Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer | 1.1 | 12 | Citations (PDF) |
| 22 | The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant | 4.2 | 30 | Citations (PDF) |
| 23 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element | 6.5 | 7 | Citations (PDF) |
| 24 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment | 4.7 | 21 | Citations (PDF) |
| 25 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk | 5.5 | 21 | Citations (PDF) |
| 26 | Genetic insights into biological mechanisms governing human ovarian ageing | 37.9 | 381 | Citations (PDF) |
| 27 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis | 3.4 | 4 | Citations (PDF) |
| 28 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness | 3.8 | 50 | Citations (PDF) |
| 29 | Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent | 4.6 | 50 | Citations (PDF) |
| 30 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes | 25.2 | 171 | Citations (PDF) |
| 31 | Chromatin interactome mapping at 139 independent breast cancer risk signals | 8.1 | 40 | Citations (PDF) |
| 32 | A Mendelian randomization analysis of circulating lipid traits and breast cancer risk | 4.9 | 72 | Citations (PDF) |
| 33 | Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families | 16.9 | 409 | Citations (PDF) |
| 34 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants | 4.2 | 121 | Citations (PDF) |
| 35 | Immune Cell Associations with Cancer Risk | 3.5 | 11 | Citations (PDF) |
| 36 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk | 6.5 | 61 | Citations (PDF) |
| 37 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer | 6.4 | 8 | Citations (PDF) |
| 38 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses | 25.2 | 471 | Citations (PDF) |
| 39 | Copy Number Variation and Ovarian Cancer Risk—Letter | 1.1 | 2 | Citations (PDF) |
| 40 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE) | 6.8 | 73 | Citations (PDF) |
| 41 | SNPs in lncRNA Regions and Breast Cancer Risk | 2.3 | 17 | Citations (PDF) |
| 42 | Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants | 14.3 | 64 | Citations (PDF) |
| 43 | Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival | 3.0 | 25 | Citations (PDF) |
| 44 | Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D | 4.6 | 154 | Citations (PDF) |
| 45 | Transcriptome‐wide association study of breast cancer risk by estrogen‐receptor status | 3.1 | 43 | Citations (PDF) |
| 46 | Candidate Causal Variants at the 8p12 Breast Cancer Risk Locus Regulate DUSP4 | 3.8 | 7 | Citations (PDF) |
| 47 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis | 13.7 | 36 | Citations (PDF) |
| 48 | Non-coding RNAs underlie genetic predisposition to breast cancer | 8.1 | 32 | Citations (PDF) |
| 49 | Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children | 3.8 | 8 | Citations (PDF) |
| 50 | Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk | 3.8 | 58 | Citations (PDF) |
| 51 | LobSig is a multigene predictor of outcome in invasive lobular carcinoma | 6.4 | 44 | Citations (PDF) |
| 52 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer | 6.4 | 44 | Citations (PDF) |
| 53 | “I am not a statistic” ovarian cancer survivors’ views of factors that influenced their long-term survival | 3.0 | 21 | Citations (PDF) |
| 54 | The molecular origin and taxonomy of mucinous ovarian carcinoma | 13.7 | 172 | Citations (PDF) |
| 55 | Shared heritability and functional enrichment across six solid cancers | 13.7 | 108 | Citations (PDF) |
| 56 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers | 5.5 | 22 | Citations (PDF) |
| 57 | BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry | 4.5 | 39 | Citations (PDF) |
| 58 | Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers | 9.9 | 83 | Citations (PDF) |
| 59 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer | 13.7 | 118 | Citations (PDF) |
| 60 | Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women | 3.0 | 44 | Citations (PDF) |
| 61 | Genome-wide association study of germline variants and breast cancer-specific mortality | 5.5 | 62 | Citations (PDF) |
| 62 | Germline deletion of ETV6 in familial acute lymphoblastic leukemia | 5.0 | 30 | Citations (PDF) |
| 63 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | 6.5 | 1,034 | Citations (PDF) |
| 64 | Is Schizophrenia a Risk Factor for Breast Cancer?—Evidence From Genetic Data | 3.9 | 26 | Citations (PDF) |
| 65 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study | 4.6 | 39 | Citations (PDF) |
| 66 | Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus | 3.8 | 30 | Citations (PDF) |
| 67 | A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants | 4.3 | 18 | Citations (PDF) |
| 68 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis | 4.9 | 95 | Citations (PDF) |
| 69 | The BRCA2
c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity | 4.5 | 20 | Citations (PDF) |
| 70 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer | 3.7 | 28 | Citations (PDF) |
| 71 | The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers | 4.6 | 120 | Citations (PDF) |
| 72 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study | 5.5 | 18 | Citations (PDF) |
| 73 | Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer | 3.4 | 5 | Citations (PDF) |
| 74 | Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium | 3.9 | 12 | Citations (PDF) |
| 75 | Mixed ductal‐lobular carcinomas: evidence for progression from ductal to lobular morphology | 4.9 | 47 | Citations (PDF) |
| 76 | Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers | 4.7 | 42 | Citations (PDF) |
| 77 | Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study | 4.9 | 18 | Citations (PDF) |
| 78 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk | 3.8 | 64 | Citations (PDF) |
| 79 | Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten | 3.2 | 46 | Citations (PDF) |
| 80 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility | 2.3 | 11 | Citations (PDF) |
| 81 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology | 4.4 | 3 | Citations (PDF) |
| 82 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer | 25.2 | 230 | Citations (PDF) |
| 83 | Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab | 4.2 | 60 | Citations (PDF) |
| 84 | Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers | 3.0 | 30 | Citations (PDF) |
| 85 | BRCA2
Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer | 3.8 | 90 | Citations (PDF) |
| 86 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk | 25.2 | 534 | Citations (PDF) |
| 87 | Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes | 25.2 | 716 | Citations (PDF) |
| 88 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer | 25.2 | 503 | Citations (PDF) |
| 89 | Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci | 1.1 | 6 | Citations (PDF) |
| 90 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer | 14.3 | 352 | Citations (PDF) |
| 91 | Association analysis identifies 65 new breast cancer risk loci | 37.9 | 1,431 | Citations (PDF) |
| 92 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | 25.2 | 405 | Citations (PDF) |
| 93 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers | 1.1 | 323 | Citations (PDF) |
| 94 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers | 4.6 | 298 | Citations (PDF) |
| 95 | Body mass index and breast cancer survival: a Mendelian randomization analysis | 4.9 | 57 | Citations (PDF) |
| 96 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study | 4.7 | 46 | Citations (PDF) |
| 97 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent | 8.0 | 139 | Citations (PDF) |
| 98 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 2.3 | 12 | Citations (PDF) |
| 99 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus | 2.3 | 12 | Citations (PDF) |
| 100 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study | 4.9 | 83 | Citations (PDF) |
| 101 | Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer | 4.3 | 54 | Citations (PDF) |
| 102 | Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk | 2.9 | 24 | Citations (PDF) |
| 103 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | 3.8 | 208 | Citations (PDF) |
| 104 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus | 4.7 | 37 | Citations (PDF) |
| 105 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes | 2.9 | 28 | Citations (PDF) |
| 106 | Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant | 6.5 | 251 | Citations (PDF) |
| 107 | Genetic predisposition to ductal carcinoma in situ of the breast | 4.7 | 54 | Citations (PDF) |
| 108 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry | 1.7 | 24 | Citations (PDF) |
| 109 | The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin | 3.8 | 272 | Citations (PDF) |
| 110 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 | 4.7 | 100 | Citations (PDF) |
| 111 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study | 4.9 | 126 | Citations (PDF) |
| 112 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression | 2.9 | 34 | Citations (PDF) |
| 113 | rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk | 3.4 | 2 | Citations (PDF) |
| 114 | Systematic review with meta‐analysis: fundic gland polyps and proton pump inhibitors | 3.7 | 81 | Citations (PDF) |
| 115 | A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer | 4.3 | 10 | Citations (PDF) |
| 116 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types | 25.1 | 192 | Citations (PDF) |
| 117 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women | 4.7 | 68 | Citations (PDF) |
| 118 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer | 13.7 | 103 | Citations (PDF) |
| 119 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus | 13.7 | 90 | Citations (PDF) |
| 120 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs) | 3.4 | 21 | Citations (PDF) |
| 121 | High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations | 4.7 | 9 | Citations (PDF) |
| 122 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing | 3.8 | 102 | Citations (PDF) |
| 123 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 | 25.2 | 150 | Citations (PDF) |
| 124 | Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer | 1.1 | 13 | Citations (PDF) |
| 125 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers | 4.6 | 82 | Citations (PDF) |
| 126 | Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families | 3.8 | 73 | Citations (PDF) |
| 127 | Evidence of a genetic link between endometriosis and ovarian cancer | 2.9 | 47 | Citations (PDF) |
| 128 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer | 3.0 | 20 | Citations (PDF) |
| 129 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 | 2.3 | 20 | Citations (PDF) |
| 130 | RAD51B in Familial Breast Cancer | 2.3 | 29 | Citations (PDF) |
| 131 | Investigation of gene‐environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors | 4.3 | 37 | Citations (PDF) |
| 132 | Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance | 4.9 | 118 | Citations (PDF) |
| 133 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers | 4.7 | 28 | Citations (PDF) |
| 134 | Common germline polymorphisms associated with breast cancer-specific survival | 4.7 | 29 | Citations (PDF) |
| 135 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair | 0.5 | 1 | Citations (PDF) |
| 136 | Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers | 2.3 | 40 | Citations (PDF) |
| 137 | A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of Telomerase | 3.2 | 42 | Citations (PDF) |
| 138 | Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants | 4.6 | 486 | Citations (PDF) |
| 139 | Cep55 regulates embryonic growth and development by promoting Akt stability in zebrafish | 0.6 | 28 | Citations (PDF) |
| 140 | Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci | 2.9 | 47 | Citations (PDF) |
| 141 | Germline Mutation in
BRCA1
or
BRCA2
and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer | 6.8 | 156 | Citations (PDF) |
| 142 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 | 2.9 | 41 | Citations (PDF) |
| 143 | Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1 | 6.5 | 84 | Citations (PDF) |
| 144 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer | 2.8 | 18 | Citations (PDF) |
| 145 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer | 25.2 | 247 | Citations (PDF) |
| 146 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | 25.2 | 584 | Citations (PDF) |
| 147 | Network-Based Integration of GWAS and Gene Expression Identifies a
HOX
-Centric Network Associated with Serous Ovarian Cancer Risk | 1.1 | 32 | Citations (PDF) |
| 148 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium | 6.8 | 38 | Citations (PDF) |
| 149 | Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study | 2.9 | 144 | Citations (PDF) |
| 150 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression | 6.5 | 40 | Citations (PDF) |
| 151 | Identification of Novel Genetic Markers of Breast Cancer Survival | 4.6 | 65 | Citations (PDF) |
| 152 | Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study | 3.0 | 18 | Citations (PDF) |
| 153 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer | 16.5 | 489 | Citations (PDF) |
| 154 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy | 4.7 | 20 | Citations (PDF) |
| 155 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer | 13.7 | 70 | Citations (PDF) |
| 156 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair | 25.2 | 427 | Citations (PDF) |
| 157 | Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer | 2.8 | 28 | Citations (PDF) |
| 158 | Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans | 2.9 | 77 | Citations (PDF) |
| 159 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis | 7.1 | 58 | Citations (PDF) |
| 160 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer | 2.9 | 78 | Citations (PDF) |
| 161 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization | 4.6 | 114 | Citations (PDF) |
| 162 | Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk | 1.1 | 26 | Citations (PDF) |
| 163 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk | 2.9 | 40 | Citations (PDF) |
| 164 | Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib | 2.3 | 35 | Citations (PDF) |
| 165 | MicroRNA Related Polymorphisms and Breast Cancer Risk | 2.3 | 52 | Citations (PDF) |
| 166 | Growing Recognition of the Role for Rare Missense Substitutions in Breast Cancer Susceptibility | 1.5 | 26 | Citations (PDF) |
| 167 | Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer | 5.6 | 79 | Citations (PDF) |
| 168 | Most common ‘sporadic’ cancers have a significant germline genetic component | 2.9 | 100 | Citations (PDF) |
| 169 | Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study | 5.5 | 108 | Citations (PDF) |
| 170 | Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast | 3.2 | 45 | Citations (PDF) |
| 171 | DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 3.2 | 55 | Citations (PDF) |
| 172 | Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer | 1.1 | 14 | Citations (PDF) |
| 173 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy | 13.7 | 16 | Citations (PDF) |
| 174 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium | 2.9 | 58 | Citations (PDF) |
| 175 | ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer | 4.6 | 126 | Citations (PDF) |
| 176 | A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy | 15.5 | 78 | Citations (PDF) |
| 177 | Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | 4.7 | 111 | Citations (PDF) |
| 178 | Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with
IL1A
and
TNFSF10 | 3.8 | 59 | Citations (PDF) |
| 179 | Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome | 4.2 | 28 | Citations (PDF) |
| 180 | DNA mismatch repair gene MSH6 implicated in determining age at natural menopause | 2.9 | 67 | Citations (PDF) |
| 181 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers | 4.7 | 63 | Citations (PDF) |
| 182 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium | 2.9 | 34 | Citations (PDF) |
| 183 | Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions | 3.1 | 28 | Citations (PDF) |
| 184 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium | 5.5 | 22 | Citations (PDF) |
| 185 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche | 37.9 | 627 | Citations (PDF) |
| 186 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation | 13.7 | 110 | Citations (PDF) |
| 187 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade | 2.9 | 14 | Citations (PDF) |
| 188 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study | 4.7 | 14 | Citations (PDF) |
| 189 | Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer | 3.4 | 32 | Citations (PDF) |
| 190 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration | 4.7 | 39 | Citations (PDF) |
| 191 | Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP–CGH analysis | 3.2 | 30 | Citations (PDF) |
| 192 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study | 27.4 | 404 | Citations (PDF) |
| 193 | ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas | 3.0 | 65 | Citations (PDF) |
| 194 | A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia | 25.2 | 312 | Citations (PDF) |
| 195 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer | 25.2 | 349 | Citations (PDF) |
| 196 | Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1 | 6.5 | 105 | Citations (PDF) |
| 197 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | 25.2 | 523 | Citations (PDF) |
| 198 | Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers | 6.5 | 209 | Citations (PDF) |
| 199 | Genome-wide association studies identify four ER negative–specific breast cancer risk loci | 25.2 | 402 | Citations (PDF) |
| 200 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk | 25.2 | 1,027 | Citations (PDF) |
| 201 | Treatment of Triple-Negative Breast Cancer Using Anti-EGFR–Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor | 5.1 | 77 | Citations (PDF) |
| 202 | Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk | 3.2 | 115 | Citations (PDF) |
| 203 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk | 3.2 | 261 | Citations (PDF) |
| 204 | A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk | 2.9 | 145 | Citations (PDF) |
| 205 | Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer | 1.1 | 58 | Citations (PDF) |
| 206 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer | 13.7 | 155 | Citations (PDF) |
| 207 | Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer | 5.5 | 6 | Citations (PDF) |
| 208 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 | 13.7 | 108 | Citations (PDF) |
| 209 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA | 2.9 | 24 | Citations (PDF) |
| 210 | A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers | 1.1 | 24 | Citations (PDF) |
| 211 | 19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus | 3.8 | 105 | Citations (PDF) |
| 212 | Common Variants at the 19p13.1 and
ZNF365
Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in
BRCA1
and
BRCA2
Mutation Carriers | 1.1 | 53 | Citations (PDF) |
| 213 | Pathology of Breast and Ovarian Cancers among
BRCA1
and
BRCA2
Mutation Carriers: Results from the Consortium of Investigators of Modifiers of
BRCA1
/
2
(CIMBA) | 1.1 | 619 | Citations (PDF) |
| 214 | The role of genetic breast cancer susceptibility variants as prognostic factors | 2.9 | 85 | Citations (PDF) |
| 215 | A Genome-Wide Association Study of Caffeine-Related Sleep Disturbance: Confirmation of a Role for a Common Variant in the Adenosine Receptor | 0.9 | 85 | Citations (PDF) |
| 216 | Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer | 16.5 | 629 | Citations (PDF) |
| 217 | Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers | 4.7 | 24 | Citations (PDF) |
| 218 | Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression | 2.3 | 122 | Citations (PDF) |
| 219 | Genome-wide association analysis identifies three new breast cancer susceptibility loci | 25.2 | 272 | Citations (PDF) |
| 220 | Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome | 16.8 | 285 | Citations (PDF) |
| 221 | 9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium | 1.1 | 17 | Citations (PDF) |
| 222 | The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes | 2.9 | 4 | Citations (PDF) |
| 223 | Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 | 2.3 | 12 | Citations (PDF) |
| 224 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer | 4.5 | 36 | Citations (PDF) |
| 225 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study | 5.5 | 29 | Citations (PDF) |
| 226 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers | 2.3 | 10 | Citations (PDF) |
| 227 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers | 4.7 | 83 | Citations (PDF) |
| 228 | Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers | 4.5 | 35 | Citations (PDF) |
| 229 | Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) | 2.3 | 52 | Citations (PDF) |
| 230 | Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer | 1.1 | 27 | Citations (PDF) |
| 231 | Breast cancer stem cells: treatment resistance and therapeutic opportunities | 2.8 | 125 | Citations (PDF) |
| 232 | Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies | 4.6 | 630 | Citations (PDF) |
| 233 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium | 2.9 | 156 | Citations (PDF) |
| 234 | Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort | 2.9 | 22 | Citations (PDF) |
| 235 | Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges | 2.3 | 6 | Citations (PDF) |
| 236 | Exploring the link between MORF4L1 and risk of breast cancer | 4.7 | 26 | Citations (PDF) |
| 237 | Rare variants in the ATMgene and risk of breast cancer | 4.7 | 216 | Citations (PDF) |
| 238 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 | 4.7 | 76 | Citations (PDF) |
| 239 | Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers | 2.3 | 54 | Citations (PDF) |
| 240 | Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2 | 5.5 | 7 | Citations (PDF) |
| 241 | Association of KRAS SNP rs61764370 with risk of invasive epithelial ovarian cancer: Implications for clinical testing | 3.0 | 0 | Citations (PDF) |
| 242 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers | 2.9 | 19 | Citations (PDF) |
| 243 | Xenobiotic‐Metabolizing gene polymorphisms and ovarian cancer risk | 3.1 | 37 | Citations (PDF) |
| 244 | Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer | 4.3 | 55 | Citations (PDF) |
| 245 | Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients | 6.8 | 58 | Citations (PDF) |
| 246 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers | 2.9 | 70 | Citations (PDF) |
| 247 | Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality | 1.1 | 32 | Citations (PDF) |
| 248 | Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk | 2.9 | 23 | Citations (PDF) |
| 249 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium† | 2.9 | 73 | Citations (PDF) |
| 250 | The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing | 6.8 | 48 | Citations (PDF) |
| 251 | 7q21-rs6964587 and breast cancer risk: an extended case–control study by the Breast Cancer Association Consortium | 3.8 | 5 | Citations (PDF) |
| 252 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers | 2.9 | 37 | Citations (PDF) |
| 253 | Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers | 4.6 | 43 | Citations (PDF) |
| 254 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk | 5.5 | 5 | Citations (PDF) |
| 255 | Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer | 2.5 | 36 | Citations (PDF) |
| 256 | Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer | 5.0 | 100 | Citations (PDF) |
| 257 | Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM | 7.8 | 126 | Citations (PDF) |
| 258 | Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis | 2.3 | 39 | Citations (PDF) |
| 259 | Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium | 2.3 | 5 | Citations (PDF) |
| 260 | Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium | 2.3 | 22 | Citations (PDF) |
| 261 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study | 4.7 | 86 | Citations (PDF) |
| 262 | DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles Defined by Mutation Status | 6.5 | 83 | Citations (PDF) |
| 263 | Gene expression profiling of formalin‐fixed, paraffin‐embedded familial breast tumours using the whole genome‐DASL assay | 4.9 | 63 | Citations (PDF) |
| 264 | Common variants at 19p13 are associated with susceptibility to ovarian cancer | 25.2 | 251 | Citations (PDF) |
| 265 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 | 25.2 | 341 | Citations (PDF) |
| 266 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population | 25.2 | 318 | Citations (PDF) |
| 267 | Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for
BRCA1
and
BRCA2
Mutation Carriers: Implications for Risk Prediction | 3.8 | 176 | Citations (PDF) |
| 268 | Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers | 2.9 | 65 | Citations (PDF) |
| 269 | Polymorphism in the GALNT1 Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium | 1.1 | 24 | Citations (PDF) |
| 270 | Genetic Variation in
TYMS
in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium | 1.1 | 25 | Citations (PDF) |
| 271 | Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers | 1.1 | 40 | Citations (PDF) |
| 272 | Missense Variants in ATM in 26,101 Breast Cancer Cases and 29,842 Controls | 1.1 | 36 | Citations (PDF) |
| 273 | Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer | 3.2 | 89 | Citations (PDF) |
| 274 | Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility “Hot-Spot” | 3.2 | 50 | Citations (PDF) |
| 275 | ESR1/SYNE1 Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study | 1.1 | 91 | Citations (PDF) |
| 276 | Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor–Negative Breast Cancer Survival | 4.6 | 52 | Citations (PDF) |
| 277 | Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers | 4.7 | 27 | Citations (PDF) |
| 278 | Common genetic variants and cancer risk in Mendelian cancer syndromes | 3.2 | 25 | Citations (PDF) |
| 279 | HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer | 4.7 | 143 | Citations (PDF) |
| 280 | The CYP17A1 −34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers | 2.3 | 3 | Citations (PDF) |
| 281 | Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study | 2.9 | 44 | Citations (PDF) |
| 282 | Association of ESR1 gene tagging SNPs with breast cancer risk | 2.9 | 87 | Citations (PDF) |
| 283 | Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042 | 4.6 | 101 | Citations (PDF) |
| 284 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers | 2.9 | 100 | Citations (PDF) |
| 285 | Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development | 4.0 | 5 | Citations (PDF) |
| 286 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 | 25.2 | 447 | Citations (PDF) |
| 287 | A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 | 25.2 | 298 | Citations (PDF) |
| 288 | Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium | 5.5 | 49 | Citations (PDF) |
| 289 | The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers | 5.5 | 20 | Citations (PDF) |
| 290 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) | 5.5 | 16 | Citations (PDF) |
| 291 | Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast Cancer | 6.5 | 178 | Citations (PDF) |
| 292 | Role of genetic polymorphisms and ovarian cancer susceptibility | 4.1 | 70 | Citations (PDF) |
| 293 | Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium | 1.1 | 59 | Citations (PDF) |
| 294 | Subtypes of familial breast tumours revealed by expression and copy number profiling | 2.3 | 88 | Citations (PDF) |
| 295 | Consortium analysis of 7 candidate SNPs for ovarian cancer | 4.3 | 79 | Citations (PDF) |
| 296 | Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 6.5 | 267 | Citations (PDF) |
| 297 | Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis | 5.5 | 51 | Citations (PDF) |
| 298 | Association of a Common AKAP9 Variant With Breast Cancer Risk: A Collaborative Analysis | 4.6 | 49 | Citations (PDF) |
| 299 | Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors | 3.1 | 119 | Citations (PDF) |
| 300 | Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics | 3.2 | 325 | Citations (PDF) |
| 301 | BRCA1 and BRCA2 Missense Variants of High and Low Clinical Significance Influence Lymphoblastoid Cell Line Post-Irradiation Gene Expression | 3.2 | 12 | Citations (PDF) |
| 302 | Clinical Classification ofBRCA1andBRCA2DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis—A Report From the kConFab Investigators | 16.9 | 73 | Citations (PDF) |
| 303 | What’s in a cancer syndrome? Genes, phenotype and pathology | 1.6 | 1 | Citations (PDF) |
| 304 | The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case–control and family analysis | 2.3 | 21 | Citations (PDF) |
| 305 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study | 2.3 | 12 | Citations (PDF) |
| 306 | No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers | 2.3 | 9 | Citations (PDF) |
| 307 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk | 2.3 | 12 | Citations (PDF) |
| 308 | AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study | 1.1 | 36 | Citations (PDF) |
| 309 | A Novel Corepressor, BCoR-L1, Represses Transcription through an Interaction with CtBP | 2.2 | 83 | Citations (PDF) |
| 310 | Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set | 1.1 | 67 | Citations (PDF) |
| 311 | Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer | 3.8 | 81 | Citations (PDF) |
| 312 | The role of glutathione-S-transferase polymorphisms in ovarian cancer survival | 4.9 | 43 | Citations (PDF) |
| 313 | Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes | 8.6 | 12 | Citations (PDF) |
| 314 | RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies | 6.5 | 222 | Citations (PDF) |
| 315 | Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? | 4.7 | 65 | Citations (PDF) |
| 316 | BCoR-L1 variation and breast cancer | 4.7 | 10 | Citations (PDF) |
| 317 | An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) | 4.7 | 149 | Citations (PDF) |
| 318 | A Systematic Approach to Analysing Gene-Gene Interactions: Polymorphisms at the Microsomal Epoxide Hydrolase EPHX and Glutathione S-transferase GSTM1, GSTT1, and GSTP1 Loci and Breast Cancer Risk | 1.1 | 40 | Citations (PDF) |
| 319 | A common coding variant in CASP8 is associated with breast cancer risk | 25.2 | 603 | Citations (PDF) |
| 320 | Patterns of somatic mutation in human cancer genomes | 37.9 | 2,938 | Citations (PDF) |
| 321 | Genome-wide association study identifies novel breast cancer susceptibility loci | 37.9 | 2,218 | Citations (PDF) |
| 322 | The MnSOD Val9Ala polymorphism, dietary antioxidant intake, risk and survival in ovarian cancer (Australia) | 3.0 | 17 | Citations (PDF) |
| 323 | Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies | 2.3 | 38 | Citations (PDF) |
| 324 | Variation in the RAD51 gene and familial breast cancer | 4.7 | 27 | Citations (PDF) |
| 325 | Analysis of cancer risk and BRCA1 and BRCA2mutation prevalence in the kConFab familial breast cancer resource | 4.7 | 141 | Citations (PDF) |
| 326 | Mutation and expression analysis of LZTS1 in ovarian cancer | 8.6 | 5 | Citations (PDF) |
| 327 | Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses | 3.4 | 168 | Citations (PDF) |
| 328 | A genome wide linkage search for breast cancer susceptibility genes | 3.0 | 114 | Citations (PDF) |
| 329 | Characterization of the breast cancer associatedATM7271T>G (V2424G) mutation by gene expression profiling | 3.0 | 20 | Citations (PDF) |
| 330 | Population-based estimates of breast cancer risks associated withATMgene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry | 4.5 | 96 | Citations (PDF) |
| 331 | The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers | 1.1 | 26 | Citations (PDF) |
| 332 | Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability | 2.3 | 8 | Citations (PDF) |
| 333 | Mutation analysis of five candidate genes in familial breast cancer | 2.3 | 15 | Citations (PDF) |
| 334 | Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma | 5.5 | 29 | Citations (PDF) |
| 335 | BRAF polymorphisms and the risk of ovarian cancer of low malignant potential | 3.0 | 13 | Citations (PDF) |
| 336 | A protein-truncating mutation inCYP17A1 in three sisters with early-onset breast cancer | 4.5 | 12 | Citations (PDF) |
| 337 | TwoATM variants and breast cancer risk | 4.5 | 44 | Citations (PDF) |
| 338 | DHPLC Analysis of patients with Nevoid Basal Cell Carcinoma Syndrome reveals novelPTCHmissense mutations in the sterol-sensing domain | 4.5 | 37 | Citations (PDF) |
| 339 | Ratio of male to female births in the offspring of BRCA1 and BRCA2 carriers | 1.4 | 6 | Citations (PDF) |
| 340 | Common Polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not Associated with Breast Cancer Risk | 1.1 | 23 | Citations (PDF) |
| 341 | Common chromosomal fragile site FRA16D mutation in cancer cells | 2.9 | 73 | Citations (PDF) |
| 342 | Double-Strand Break Repair Gene Polymorphisms and Risk of Breast or Ovarian Cancer | 1.1 | 78 | Citations (PDF) |
| 343 | Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals | 5.5 | 38 | Citations (PDF) |
| 344 | Classification of BRCA1 missense variants of unknown clinical significance | 3.8 | 79 | Citations (PDF) |
| 345 | RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women | 8.6 | 8 | Citations (PDF) |
| 346 | Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer | 4.7 | 46 | Citations (PDF) |
| 347 | Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1gene with missense sequence changes and in-frame deletions, but not polymorphisms | 4.7 | 24 | Citations (PDF) |
| 348 | CYP17genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study | 4.7 | 24 | Citations (PDF) |
| 349 | Title is missing! | 4.7 | 46 | Citations (PDF) |
| 350 | Intragenic ERBB2 kinase mutations in tumours | 37.9 | 803 | Citations (PDF) |
| 351 | ATM and Genome Maintenance: Defining Its Role in Breast Cancer Susceptibility | 3.1 | 31 | Citations (PDF) |
| 352 | Germ-line mutations inBRCA1 orBRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A | 3.0 | 97 | Citations (PDF) |
| 353 | Mapping of a candidate colorectal cancer tumor-suppressor gene to a 900-kilobase region on the short arm of chromosome 8 | 3.0 | 35 | Citations (PDF) |
| 354 | No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer | 4.7 | 10 | Citations (PDF) |
| 355 | The prohibitin 3′ untranslated region polymorphism is not associated with risk of ovarian cancer | 3.0 | 19 | Citations (PDF) |
| 356 | Transfer of chromosome 8 into two breast cancer cell lines | 1.2 | 9 | Citations (PDF) |
| 357 | Regressive logistic and proportional hazards disease models for within‐family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer | 3.1 | 22 | Citations (PDF) |
| 358 | Analysis of the transcription regulator,CNOT7, as a candidate chromosome 8 tumor suppressor gene in colorectal cancer | 4.3 | 16 | Citations (PDF) |
| 359 | Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer | 5.5 | 37 | Citations (PDF) |
| 360 | Dominant Negative ATM Mutations in Breast Cancer Families | 4.6 | 259 | Citations (PDF) |
| 361 | The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer | 6.7 | 127 | Citations (PDF) |
| 362 | No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer | 4.7 | 17 | Citations (PDF) |
| 363 | Prohibitin 3′ untranslated region polymorphism and breast cancer risk in Australian women | 62.1 | 25 | Citations (PDF) |
| 364 | Chromosome 8 genetic analysis and phenotypic characterization of 21 ovarian cancer cell lines | 1.2 | 4 | Citations (PDF) |
| 365 | Mutations of the BRAF gene in human cancer | 37.9 | 10,125 | Citations (PDF) |
| 366 | Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas | 5.5 | 64 | Citations (PDF) |
| 367 | The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia | 4.7 | 13 | Citations (PDF) |
| 368 | The microsomal epoxide hydrolase Tyr113His polymorphism: Association with risk of ovarian cancer | 3.1 | 38 | Citations (PDF) |
| 369 | Analysis of the TGF β functional pathway in epithelial ovarian carcinoma | 5.5 | 28 | Citations (PDF) |
| 370 | Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas | 5.5 | 28 | Citations (PDF) |
| 371 | Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype | 2.8 | 77 | Citations (PDF) |
| 372 | No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer | 2.8 | 36 | Citations (PDF) |
| 373 | CYP17 promotor polymorphism and ovarian cancer risk 2000, 86, 436-439 | | 35 | Citations (PDF) |
| 374 | Sequence variants ofDLC1 in colorectal and ovarian tumours | 4.5 | 30 | Citations (PDF) |
| 375 | Androgen receptor exon 1 cag repeat length and risk of ovarian cancer | 4.3 | 39 | Citations (PDF) |
| 376 | The spectrum ofpatched mutations in a collection of Australian basal cell carcinomas | 4.5 | 24 | Citations (PDF) |
| 377 | kConFab:
a research resource of Australasian breast cancer families | 1.7 | 36 | Citations (PDF) |
| 378 | CYP17 Promoter Polymorphism and Breast Cancer in Australian Women Under Age Forty Years | 4.6 | 54 | Citations (PDF) |
| 379 | Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer | 2.8 | 111 | Citations (PDF) |
| 380 | Expression of p53 in Arsenic-Related and Sporadic Basal Cell Carcinoma | 1.5 | 48 | Citations (PDF) |
| 381 | Evidence for microsatellite instability in bilateral breast carcinomas | 8.6 | 21 | Citations (PDF) |
| 382 | Androgen Receptor Exon 1 CAG Repeat Length and Breast Cancer in Women Before Age Forty Years | 4.6 | 71 | Citations (PDF) |
| 383 | Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32 | 2.9 | 182 | Citations (PDF) |
| 384 | ?-Catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours | 4.3 | 121 | Citations (PDF) |
| 385 | Design and Analysis Issues in a Population-Based, Case-Control-Family Study of the Genetic Epidemiology of Breast Cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS) | 1.7 | 77 | Citations (PDF) |
| 386 | The effects of splice site mutations in patients with naevoid basal cell carcinoma syndrome | 2.9 | 24 | Citations (PDF) |
| 387 | No Evidence for Microsatellite Instability from Allelotype Analysis of Benign and Low Malignant Potential Ovarian Neoplasms | 3.0 | 27 | Citations (PDF) |
| 388 | Urokinase receptor genotypes in colorectal cancer | 2.8 | 0 | Citations (PDF) |
| 389 | Relationship Between Number of Ovulatory Cycles and Accumulation of Mutant p53 in Epithelial Ovarian Cancer | 4.6 | 42 | Citations (PDF) |
| 390 | Fertility and Incidence of KRAS2 Mutations in Borderline Ovarian Adenocarcinomas | 4.6 | 0 | Citations (PDF) |
| 391 | De novo mutations of thepatched gene in nevoid basal cell carcinoma syndrome help to define the clinical phenotype 1997, 73, 304-307 | | 43 | Citations (PDF) |
| 392 | Analysis of loss of heterozygosity andKRAS2 mutations in ovarian neoplasms: Clinicopathological correlations 1997, 18, 75-83 | | 42 | Citations (PDF) |
| 393 | Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas | 3.0 | 44 | Citations (PDF) |
| 394 | Rare mutations and no hypermethylation at theCDKN2A locus in epithelial ovarian tumours | 4.3 | 36 | Citations (PDF) |
| 395 | Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma Syndrome | 33.6 | 2,198 | Citations (PDF) |
| 396 | The diagnostic implication of falcine calcification on plain skull radiographs of patients with basal cell naevus syndrome and the incidence of falcine calcification in their relatives and two control groups | 2.4 | 21 | Citations (PDF) |
| 397 | Increased expression of the nme1 gene is associated with metastasis in epithelial ovarian cancer | 4.3 | 24 | Citations (PDF) |
| 398 | AnAlu VpA Marker on chromosome 1 demonstrates that replication errors manifest at the adenoma-carcinoma transition in sporadic colorectal tumors | 3.0 | 20 | Citations (PDF) |
| 399 | Atopy in Australia | 25.2 | 23 | Citations (PDF) |
| 400 | Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region | 5.5 | 28 | Citations (PDF) |
| 401 | Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset | 2.8 | 195 | Citations (PDF) |
| 402 | Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas | 2.9 | 52 | Citations (PDF) |
| 403 | The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS | 2.4 | 30 | Citations (PDF) |
| 404 | Glutathione S-transferase GSTM1 null genotype is not overrepresented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma | 2.8 | 22 | Citations (PDF) |
| 405 | Simple repeat polymorphism at the D9S151 locus | 2.9 | 0 | Citations (PDF) |
| 406 | Nevoid basal cell carcinoma syndrome: Review of 118 affected individuals | 0.5 | 340 | Citations (PDF) |
| 407 | Distinct phenotype in maternal uniparental disomy of chromosome 14 | 0.5 | 73 | Citations (PDF) |
| 408 | Loss of heterozygosity on the long arm of chromosome 11 in colorectal tumours | 5.5 | 33 | Citations (PDF) |
| 409 | Fine Genetic Mapping of the Gene for Nevoid Basal Cell Carcinoma Syndrome | 2.8 | 54 | Citations (PDF) |
| 410 | Genomic instability occurs in colorectal carcinomas but not in adenomas | 4.5 | 125 | Citations (PDF) |
| 411 | Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell | 0.6 | 15 | Citations (PDF) |
| 412 | Exclusion of APC and MCC as the gene defect in one family with familial juvenile polyposis | 0.9 | 26 | Citations (PDF) |
| 413 | New syndrome? Basal cell carcinomas, coarse sparse hair, and milia | 0.5 | 41 | Citations (PDF) |
| 414 | Basal cell naevus syndrome | 1.7 | 0 | Citations (PDF) |
| 415 | Elevation of follicular phase inhibin and luteinizing hormone levels in mothers of dizygotic twins suggests nonovarian control of human multiple ovulation | 2.9 | 43 | Citations (PDF) |
| 416 | Analysis of gene amplification in head-and-neck squamous-cell carcinomas | 4.3 | 115 | Citations (PDF) |
| 417 | Ncol RFLP of the human LHRH gene on chromosome 8p | 15.5 | 3 | Citations (PDF) |
| 418 | Mspl RFLP of FSHB on chromosome 11p | 15.5 | 1 | Citations (PDF) |
| 419 | Pstl RFLP of the CGB gene | 15.5 | 2 | Citations (PDF) |
| 420 | Localization of the gene for human proliferating nuclear antigen/cyclin by in situ hybridization | 2.9 | 11 | Citations (PDF) |
| 421 | BamHI RFLP of the inhibin beta B (INHBB) chain gene on chromosome 2 | 15.5 | 3 | Citations (PDF) |
| 422 | Bcll RFLP of the plasminogen activator inhibitor type 2 gene (PLANH) on chromosome 18q21-q23 | 15.5 | 1 | Citations (PDF) |
| 423 | The EcoRI rflp of c-MOS in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-Geriatric controls | 4.3 | 4 | Citations (PDF) |
| 424 | Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls | 5.5 | 19 | Citations (PDF) |
| 425 | Chromosome analysis of 30 cases of non-Hodgkin’s lymphoma | 1.4 | 11 | Citations (PDF) |
| 426 | The molecular genetics of human non-Hodgkin's lymphoma | 1.2 | 6 | Citations (PDF) |
| 427 | Cytogenetic and molecular genetic studies of a patient with atypical lymphoid hyperplasia | 1.2 | 4 | Citations (PDF) |
| 428 | Somatic rearrangement of the c-myc oncogene in primary human diffuse large-cell lymphoma | 4.3 | 12 | Citations (PDF) |
| 429 | Title is missing! 0 | | 2 | Citations (PDF) |
